Last reviewed · How we verify
VINBLASTINE SULFATE
At a glance
| Generic name | VINBLASTINE SULFATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
Boxed warnings
- WARNINGS Caution: This preparation should be administered by individuals experienced in the administration of vinblastine sulfate. It is extremely important that the intravenous needle or catheter be properly positioned before any vinblastine sulfate is injected. Leakage into surrounding tissue during intravenous administration of vinblastine sulfate may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES. See WARNINGS for the treatment of patients given intrathecal vinblastine sulfate injection.
Common side effects
- Leukopenia (granulocytopenia)
- Alopecia
- Constipation
- Anorexia
- Nausea
- Vomiting
- Abdominal pain
- Anemia
- Thrombocytopenia
- Numbness of digits (paresthesias)
- Loss of deep tendon reflexes
- Peripheral neuritis
Serious adverse events
- Myocardial infarction
- Angina pectoris
- Cerebrovascular accidents
- Convulsions
- Eighth cranial nerve damage (vestibular and auditory)
- Deafness (partial or total)
- Hemorrhagic enterocolitis
- Syndrome of inappropriate secretion of antidiuretic hormone
- Cellulitis from extravasation
- Sloughing from extravasation
Key clinical trials
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (PHASE1, PHASE2)
- Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma (PHASE2)
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (PHASE3)
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis (NA)
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VINBLASTINE SULFATE CI brief — competitive landscape report
- VINBLASTINE SULFATE updates RSS · CI watch RSS